welcome
Insider

Insider

Health

Health

Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again

Insider
Summary
Nutrition label

78% Informative

Hims and Hers' stock fell over 19% in after-hours trading on Monday .

The telehealth company has been making legal copies of Novo Nordisk's weight loss and diabetes drugs.

The FDA removed semaglutide injections from its shortage list last week .

Hims ' GLP-1 drugs start at $ 199 a month, while Wegovy and Ozempic cost over $ 900 a month.

VR Score

77

Informative language

76

Neutral language

43

Article tone

formal

Language

English

Language complexity

39

Offensive language

possibly offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links